Full Breakdown
Oura’s U.S. IPO Targets $15-plus Billion Valuation, Primarily Benefits Existing Shareholders
By Drooid · · How we work
Core Offering Details
On September 21, 2026 Oura Inc. filed to sell 50 million shares at $40-$44 each. The company will offer 13.5 million shares, while existing shareholders will sell 36.5 million. At the midpoint, the implied market cap is about $14.1 billion; the filing lists a fully-diluted valuation of roughly $15 billion and $15.62 billion at the top of the range. Assuming the top price, gross proceeds could reach $2.2 billion, with $1.53 billion to selling shareholders and $567 million to Oura before fees.
Financial Profile and Growth Metrics
- Revenue: $1.21 billion for the nine-month period ending June 30, 2026, a 74 % YoY increase.
- Net loss: $924.3 million, up from $182.8 million a year earlier, reflecting a deemed dividend on redeemable convertible preferred stock.
- Membership: Over 5 million paid members as of June 30, 2026, a 100 % YoY increase; membership revenue rose to $240.5 million (121 % YoY).
- Hardware vs. subscription: Hardware generated roughly $974 million; subscription services contributed about $240 million, delivering an 89 % gross margin.
Background & Context
Founded in 2013 in Oulu, Finland, by engineers Petteri Lahtela, Kari Kivelä and Markku Koskela, Oura created a finger-worn sensor ring that tracks sleep, activity, heart health and women’s health metrics. The firm’s valuation reached $11 billion after a late-stage round in October 2025 led by Fidelity Management & Research, which raised over $900 million. Earlier rounds in 2024 and 2025 valued the company at $5.2 billion and $5.9 billion.
Investor Interest
Pharmaceutical firm Eli Lilly has indicated intent to purchase up to $100 million of shares, while Dragoneer Investment Group has signaled interest in buying up to $300 million, together representing roughly 19 % of the total offering.
Official Statements & Responses
The prospectus states Oura will use the net proceeds of roughly $532 million to settle accumulated tax obligations tied to employee share grants that vest at the IPO, leaving about $6 million for general corporate purposes. The company will not receive any proceeds from the secondary shares sold by existing shareholders.
Criticism & Opposition
A class-action lawsuit alleges Oura misled consumers about the accuracy of its sleep-stage and sleep-quality measurements. Oura has denied wrongdoing and defended the scientific basis of its data.
Conflicting Reports & Gaps
- Valuation: The filing targets a fully-diluted valuation of $15.62 billion; share-count calculations suggest a market cap of $14.1 billion at the top of the range; other analyses cite a fully-diluted figure of about $15 billion.
- Future performance: Projections of sustained 74 % revenue growth and near-doubling of paid members are based on company guidance; independent analyst forecasts are not provided.
Verbatim Quotes
- “Oura is the first real test of US appetite after a sluggish September so far and a period of more volatile markets. If it comes strongly out the gate, it will encourage other issuers,” — Samuel Kerr, global head of equity capital markets at Mergermarket
- “One of Oura's strengths is that it is beginner friendly, fashionable and feels more like an easy add-on to everyday life, compared with some wearables that are more geared toward serious athletes and performance tracking,” — Kat Liu, vice president at IPOX
What’s Next
The offering is expected to price during the week of Monday September 28, 2026 and begin trading on the Nasdaq Global Select Market under the ticker “OURA.” The underwriters have a 30-day option to purchase up to an additional 7.5 million shares from selling shareholders.